Navigation Links
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Date:9/16/2008

TORONTO, Sept. 16 /PRNewswire/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated catheters, both products achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data on file).

"Due to the recent contamination, subsequent price increases, and safety issues for Heparin, catheter manufacturers are seeking alternative coatings for their products. Interface Biologics' Endexo(TM) anti-thrombic additives are non-drug polymers that have anti platelet properties. These polymers are compatible with a wide range of base polymers, and since they are an additive rather than a coating, afford ease of process manufacturing as well as provide both extra and intraluminal coverage, and are equivalent in thrombus reduction performance to commercially available coatings," stated Rich Sullivan, President and CEO of Interface Biologics.

The blood loop study was performed at the Medical Device Evaluation Center (MDEC) in Salt Lake City Utah. "Catheters with effective Endexo additives showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin coated catheter," stated Sivaprasad Sukavaneshvar, Ph.D., VP of MDEC.

About Interface Biologics Inc.

Interface Biologics is a biomaterials company located in Toronto, Canada. The company develops and manufactures novel anti-thrombic and anti-infective polymers used in medical devices for cardiovascular and urological applications.


'/>"/>
SOURCE Interface Biologics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Velos to Develop Key System Interface for Clinical Research
2. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
3. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
4. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
8. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
9. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
10. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
11. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
Breaking Medicine Technology:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
Breaking Medicine News(10 mins):